DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Haas NB, Manola J, Uzzo RG. et al.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet 2016;
387: 2008-2016
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.